TRINETRA › Sectors › Healthcare
Sanofi Consumer Healthcare India Limited (SANOFICONR) — share price, P/E and fundamentals
Sanofi Consumer Healthcare India Limited (NSE: SANOFICONR) closed at ₹3,402.00 on 30 Oct 2026, -27.4% over one year, against a 52-week range of ₹3,168.20 – ₹5,255.00.
In the quarter ended 30 Sept 2026 (standalone, filed 28 Oct 2026) it reported revenue of ₹263 cr and net profit of ₹77 cr, a 29.1% net margin; revenue grew 12.5% and profit grew 22.1% year on year.
On four consecutive filed quarters its trailing P/E is 28.0; since 25 Feb 2026 its own P/E has ranged from 28.0 to 45.4 (median 40.8), and today's reading is higher than 1% of those 164 trading days.
From the balance sheet dated 30 Jun 2026: return on equity 88.1%, ROCE 108.6%, debt-to-equity 0.00, Piotroski F-score 6 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 97% of 64 sector peers; PBT margin higher than 98% of 64 sector peers; ROE higher than 100% of 64 sector peers.
Key figures
| Last close | ₹3,402.00 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -14.3% / -26.0% / -27.4% |
| 52-week low – high | ₹3,168.20 – ₹5,255.00 |
| Market capitalisation | ₹7,825 cr |
| Trailing P/E | 28.0 |
| Price / book | 22.49 |
| EV / EBITDA | 18.8 |
| Earnings yield | 3.6% |
| TTM EPS | ₹121.61 |
| TTM net profit | ₹280 cr |
| Quarter revenue | ₹263 cr |
| Quarter net profit | ₹77 cr |
| Net margin | 29.1% |
| Revenue growth (YoY) | +12.5% |
| Profit growth (YoY) | +22.1% |
| Return on equity | 88.1% |
| ROCE | 108.6% |
| Debt / equity | 0.00 |
| Current ratio | 2.03 |
| Free cash flow | ₹144 cr |
| Piotroski F-score | 6 / 9 |
| Average daily turnover (50 days) | ₹1.7 cr |
Against Healthcare peers
| Metric | SANOFICONR | Peer median | Percentile |
|---|---|---|---|
| Net margin | 29.11 | 12.89 | 97 |
| PBT margin | 39.03 | 17.68 | 98 |
| ROE | 88.07 | 13.87 | 100 |
| ROCE | 108.62 | 17.26 | 100 |
| Debt / equity | 0.00 | 0.11 | 12 |
| FCF margin | 19.84 | -0.87 | 87 |
| Cash conversion | 0.68 | 1.25 | 15 |
| Trailing P/E | 27.97 | 43.26 | 20 |
Questions
What is the P/E ratio of Sanofi Consumer Healthcare India Limited?
Sanofi Consumer Healthcare India Limited's trailing P/E is 28.0, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 25 Feb 2026 its P/E has ranged 28.0–45.4.
What were Sanofi Consumer Healthcare India Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Sanofi Consumer Healthcare India Limited reported revenue of ₹263 cr and net profit of ₹77 cr (standalone), filed with the exchange on 28 Oct 2026.
What is Sanofi Consumer Healthcare India Limited's ROE?
Return on equity is 88.1% based on the balance sheet dated 30 Jun 2026.
Does Sanofi Consumer Healthcare India Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 30 Jun 2026.
What is SANOFICONR's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, SANOFICONR traded between ₹3,168.20 and ₹5,255.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: standalone SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.